FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Evren Breakthrough on Earbud PTSD Therapy

[ Price : $8.95]

FDA grants Evren Technologies a breakthrough device designation for its Phoenix earbud device and its use in treating post-traumat...

Incyte BLA for Retifanlimab Turned Down by FDA

[ Price : $8.95]

FDA issues Incyte a complete response letter on its BLA for retifanlimab, an intravenous PD-1 inhibitor for treating certain adult...

Cell Tissue Panel to Discuss Toxicity Risks

[ Price : $8.95]

Federal Register notice: FDA announces a 9/2-3 Cellular, Tissue and Gene Therapies Advisory Committee meeting.

Gloves Remain Class 1; 510(k) Required

[ Price : $8.95]

Federal Register notice: FDA rescinds a 1/15 notice that identified seven types of reserved Class 1 devices that HHS had determine...

FDA Complete Response on Iterum NDA

[ Price : $8.95]

FDA issues Iterum Therapeutics a complete response letter on its NDA for sulopenem etzadroxil/probenecid, indicated for treating t...

Comments Extended on Powered Patient Transport

[ Price : $8.95]

Federal Register notice: FDA extends the comment period for a 6/15 notice on: Exemption from Premarket Notification: Powered Patie...

Patient Advocates Sought for FDA Collaboration

[ Price : $8.95]

Federal Register notice: FDA and the Clinical Trials Transformation Initiative request applications for patient advocates interest...

MAPP on ANDA Labeling Changes

[ Price : $8.95]

FDA revises a Manual of Policies and Procedures (MAPP) entitled Generic Drug Labeling Revisions Under Section 505(j)(10) of the Fe...

BMS Pulls Opdivo Indication for Liver Cancer

[ Price : $8.95]

Bristol Myers Squibb withdraws an indication for Opdivo (nivolumab) as a single agent for patients with hepatocellular carcinoma w...

Covid Emergency Use Authorizations Listing Update

[ Price : $8.95]

Federal Register notice: FDA updates its listing of emergency use authorizations granted during the Covid-19 public health emergen...